Filing search / Innovation Pharmaceuticals Inc. / "Satisfaction"

Search information

Innovation Pharmaceuticals Inc.

Companies

"Satisfaction"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

80 results

Newest first Best match first

10-Q

2024 Q1

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction … concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have negative working capital

20 Nov 23

4:05pm

8-K

IPIX Innovation Pharmaceuticals Inc.

30 Oct 23

Changes in Registrant's Certifying Accountant

4:15pm

principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Pinnacle’s satisfaction

10-K

2023 FY

IPIX Innovation Pharmaceuticals Inc.

Annual report

and satisfaction of liabilities in the normal course of business. We have negative working capital of $3.4 million and have incurred losses since inception … of assets and satisfaction of liabilities in the normal course of business. For the fiscal year ended June 30, 2023, the Company had a net loss of $3.2

28 Sep 23

9:00am

10-Q

2023 Q3

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the nine months ended March 31, 2023 … of up to 24 months following issuance. Subject to the satisfaction of certain circumstances, the Company may call for cancellation any or all

15 May 23

8:01am

10-Q

2023 Q1

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the three … for approximately $5.0 million in aggregate exercise price, for a period of up to 24 months following issuance. Subject to the satisfaction of certain

10 Nov 22

4:06pm

10-K

0dhnldh973cuo pq

Annual report

28 Sep 22

4:00pm

Entry into a Material Definitive Agreement

13 May 22

4:07pm

10-Q

w8j1uo4hwp

Quarterly report

14 Feb 22

4:00pm

10-Q

vq0fqh0fyiuyr3 7m3ff

Quarterly report

9 Nov 21

1:44pm

10-K

p5s7v0

Annual report

27 Sep 21

4:16pm

10-Q

do5xm

Quarterly report

13 May 21

8:00am

10-Q

9gm6sdi j3h

Quarterly report

22 Feb 21

11:19am

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

14 Sep 20

4:50pm

424B5

ifhz 05jfkzyr

4 Aug 20

Prospectus supplement for primary offering

9:32am

Filing search / Innovation Pharmaceuticals Inc. / "Satisfaction"

80 results

Top filers

Top filing types

Recent filing years